First Time Loading...

Mesoblast Ltd
ASX:MSB

Watchlist Manager
Mesoblast Ltd Logo
Mesoblast Ltd
ASX:MSB
Watchlist
Price: 1.155 AUD 6.45% Market Closed
Updated: May 6, 2024

Mesoblast Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mesoblast Ltd
Operating Income Peer Comparison

Comparables:
IMM
CSL
CUV
TLX
PYC

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Mesoblast Ltd
ASX:MSB
Operating Income
-$55.3m
CAGR 3-Years
21%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Operating Income
-AU$46.9m
CAGR 3-Years
-29%
CAGR 5-Years
-24%
CAGR 10-Years
-13%
CSL Ltd
ASX:CSL
Operating Income
$3.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
9%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Operating Income
AU$50.8m
CAGR 3-Years
36%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Operating Income
AU$17.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Operating Income
-AU$21.2m
CAGR 3-Years
-28%
CAGR 5-Years
-22%
CAGR 10-Years
-17%

See Also

What is Mesoblast Ltd's Operating Income?
Operating Income
-55.3m USD

Based on the financial report for Dec 31, 2023, Mesoblast Ltd's Operating Income amounts to -55.3m USD.

What is Mesoblast Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
9%

Over the last year, the Operating Income growth was 28%. The average annual Operating Income growth rates for Mesoblast Ltd have been 21% over the past three years , 9% over the past five years .